WO2006032711A1 - Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden - Google Patents
Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden Download PDFInfo
- Publication number
- WO2006032711A1 WO2006032711A1 PCT/ES2004/000380 ES2004000380W WO2006032711A1 WO 2006032711 A1 WO2006032711 A1 WO 2006032711A1 ES 2004000380 W ES2004000380 W ES 2004000380W WO 2006032711 A1 WO2006032711 A1 WO 2006032711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- alpha
- insulin
- growth factor
- hepatitis
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 112
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 110
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 110
- 102000013275 Somatomedins Human genes 0.000 title claims abstract description 46
- 208000019423 liver disease Diseases 0.000 title claims abstract description 45
- 238000011282 treatment Methods 0.000 title claims abstract description 45
- 230000001684 chronic effect Effects 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 title claims description 14
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 31
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims abstract description 10
- 208000002353 alcoholic hepatitis Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 206010019799 Hepatitis viral Diseases 0.000 claims abstract description 9
- 201000001862 viral hepatitis Diseases 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 29
- 210000004185 liver Anatomy 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000037396 body weight Effects 0.000 claims description 15
- 241000711549 Hepacivirus C Species 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 241000700721 Hepatitis B virus Species 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 230000002608 insulinlike Effects 0.000 claims description 2
- 229950000038 interferon alfa Drugs 0.000 claims description 2
- 230000004792 oxidative damage Effects 0.000 abstract description 4
- 230000001476 alcoholic effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 60
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 47
- 241001465754 Metazoa Species 0.000 description 39
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 37
- 206010016654 Fibrosis Diseases 0.000 description 18
- 241000700159 Rattus Species 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 238000011260 co-administration Methods 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 9
- 108010082126 Alanine transaminase Proteins 0.000 description 9
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000007882 cirrhosis Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 206010008635 Cholestasis Diseases 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 231100000359 cholestasis Toxicity 0.000 description 5
- 230000007870 cholestasis Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000007449 liver function test Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000000434 anti-fibrogenic effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000012317 liver biopsy Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 229960002695 phenobarbital Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000007348 Experimental Liver Cirrhosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710127454 Interferon alpha-3 Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002615 fibrolytic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000002099 somatostatinotropic effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- WCTAGTRAWPDFQO-UHFFFAOYSA-K trisodium;hydrogen carbonate;carbonate Chemical compound [Na+].[Na+].[Na+].OC([O-])=O.[O-]C([O-])=O WCTAGTRAWPDFQO-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention is encompassed in the area of liver disease treatments, preferably liver cirrhosis and chronic liver disease with a predominance of oxidative damage (alcoholic hepatitis and C virus).
- liver disease treatments preferably liver cirrhosis and chronic liver disease with a predominance of oxidative damage (alcoholic hepatitis and C virus).
- Cirrhosis is a diffuse process of fibrosis and formation of regeneration nodules, whose pathophysiology is not well known. Liver cirrhosis is a disease of high social prevalence, with few therapeutic possibilities, in which the use of liver transplantation is the only therapeutic strategy in advanced stages.
- Type I insulin-like growth factor is an anabolic hormone, which is synthesized primarily in the liver by the stimulation of growth hormone, GH.
- IGF-I plasma concentrations are of hepatic origin.
- the hepatic parenchyma has reduced its biosynthetic capacity, as a consequence, plasma concentrations of IGF-I are decreased.
- IGF-I deficiency has been linked to the severe malnutrition process suffered by the cirrhotic patient, which overshadows the prognosis and decreases the chances of successful liver transplantation.
- IFN alpha inhibits the production of collagen.
- IFN- ⁇ therapy can suppress the progression of liver fibrosis by inhibiting fibrogenesis (12-16) and accelerating fibrolysis in chronic liver disease.
- the present invention is therefore aimed at improving the therapy used so far in said liver diseases.
- the present invention relates to the use of insulin-like growth factor type I (IGF-I) and interferon-alpha (iFN- ⁇ ), in which type I insulin-like growth factor (IGF-I) ) and interferon-alpha are used in the manufacture of drugs useful in combined administration for the treatment of chronic liver disease.
- IGF-I insulin-like growth factor type I
- iFN- ⁇ interferon-alpha
- liver cirrhosis Especially said chronic liver disease is liver cirrhosis, alcoholic hepatitis, viral hepatitis and simultaneous occurrences thereof, and particularly particularly said chronic liver disease is liver cirrhosis.
- insulin-like growth factor type I and interferon-alpha preferably between 20 and 200 ⁇ g / kg body weight of the patient of factor of insulin-like growth type I, per day.
- the chronic liver disease is hepatitis C virus, and for the administration of insulin-like growth factor type I and interferon-alpha, 2 to 6 MUI are used (MUI, millions of international units) of interferon-alpha three times per week.
- interferon-alpha for the administration of insulin-like growth factor type I and interferon-alpha, between 6 and 15 MUI of interferon-alpha are used per week. This amount of interferon-alpha can be given distributed on alternate days or in a single weekly dose.
- the disease is hepatitis C virus and for the administration of insulin-like growth factor type I and interferon-alpha, 0.2 to 1.2 ⁇ g / kg of Interferon-alpha patient's body weight per week.
- the chronic liver disease is virus hepatitis
- insulin-like growth factor type I and interferon-alpha 1.5 to 10 MUI of interferon-alpha is used three times per week.
- the chronic liver disease is hepatitis B virus
- insulin-like growth factor type I and interferon-alpha between 4.5 and 35 MUI of interferon are employed.
- -alfa per week This amount of interferon-alpha can be given distributed on alternate days or in a single weekly dose.
- the present invention also relates to a pharmaceutical kit for the treatment of chronic liver disease, wherein the kit comprises a first component comprising insulin-like growth factor type I (IGF-I); Y a second component comprising interferon-alpha (IFN- ⁇ ).
- IGF-I insulin-like growth factor type I
- IFN- ⁇ interferon-alpha
- liver cirrhosis Especially the chronic liver disease is liver cirrhosis, alcoholic hepatitis, viral hepatitis and simultaneous occurrences thereof.
- liver cirrhosis is liver cirrhosis.
- the first component comprises insulin-like growth factor type I in an amount sufficient to provide a dose of between 20 and 200 ⁇ g insulin-like growth factor type I, per kilogram of the patient's body weight, and per day.
- the chronic liver disease is hepatitis C virus
- the second component comprises interferon-alpha in an amount sufficient to provide a dose of 2 to 6 MUI of interferon-alpha three times per week.
- the second component comprises interferon-alpha in an amount sufficient to provide a dose of 6 to 15 MUI of interferon-alpha per week.
- the disease is hepatitis C virus
- the second component comprises interferon-alpha in an amount sufficient to provide a dose of 0.2 to 1.2 ⁇ g of interferon-alpha per kilogram of weight. body of the patient, per week.
- the chronic liver disease is hepatitis B virus
- the second component comprises interferon-alpha in an amount sufficient to provide a dose of 1.5 to 10 MUI of interferon-alpha 3 times per week.
- Pharmaceutical chronic liver disease is hepatitis B virus
- the second component comprises interferon-alpha in an amount sufficient to provide a dose of 4.5 to 35 MUI of interferon-alpha per week.
- said kit further comprises a third component comprising one or more pharmaceutically compatible excipients with insulin-like growth factor type I and with interferon-alpha.
- this further comprises a third component comprising one or more pharmaceutically compatible carrier agents with insulin-like growth factor type I and with interferon-alpha.
- the first component further comprises one or more pharmaceutically acceptable excipients and compatible with insulin-like growth factor type I and with interferon-alpha.
- the second component further comprises one or more pharmaceutically acceptable excipients compatible with interferon-alpha and with insulin-like growth factor type I.
- the present invention further relates to a pharmaceutical composition for the treatment of a chronic liver disease, which comprises a pharmaceutically acceptable amount of insulin-like growth factor type I (IGF-I) and a pharmaceutically acceptable amount of interferon-alpha (IFN- ⁇ ).
- IGF-I insulin-like growth factor type I
- IFN- ⁇ interferon-alpha
- liver cirrhosis Especially the chronic liver disease is liver cirrhosis, alcoholic hepatitis, viral hepatitis and simultaneous occurrences thereof, particularly preferably said disease is liver cirrhosis.
- pharmaceutical composition This comprises between 20 and 200 ⁇ g of insulin-like growth factor type I per kilogram of the patient's body weight.
- the chronic liver disease is hepatitis C virus and said composition comprises an amount of 2 to 15 MUI of interferon-alpha.
- the chronic liver disease is hepatitis C virus
- said composition comprises an amount of 0.2 to 1.2 ⁇ g of interferon-alpha, per kilogram of the patient's body weight.
- the chronic liver disease is hepatitis B
- said composition comprises an amount of 1.5 to 35 MUI of interferon-alpha.
- this further comprises a pharmaceutically compatible excipient with insulin-like growth factor type I and with interferon-alpha.
- the insulin-like growth factor type I and interferon-alpha are vehiculized in two vehicular agents.
- the pharmaceutical composition of the invention can be administered parenterally, preferably subcutaneously, transdermally or percutaneously.
- Parenteral administration forms can be obtained in a conventional manner by mixing the active ingredient or ingredients with buffers, stabilizers, preservatives, solubilizing agents, toning agents and suspending agents. These mixtures are sterilized by known techniques and packaged to be administered as injections.
- the composition may be a sterile solution, emulsion or dispersion.
- Said composition may be an injectable preparation may be prepared by dissolving, emulsifying or dispersing the active ingredient or ingredients together with one or more excipients, in water for injection.
- As buffers organophosphate-based salts can be used.
- solubilizing agents are castor oil solidified with polyoxyethylene, polysorbate 80, nicotinamide, and macrogol.
- solubilizing agents sodium sulfite, sodium metasulfite, - and as preservative agents, sorbic acid, cresol, paracresol and others can be used.
- regulatory solutions such as citric acid-sodium citrate, acetic acid-sodium acetate, and monosodium carbonate-disodium carbonate, among others, can be mentioned.
- excipients are sterilizing agents to prevent the presence of pyrogens and / or contaminants.
- Another optional component of the pharmaceutical composition for subcutaneous administration is one or more vehicular agents, such as, for example, water, hydrocarbons, alcohols, polyols, ethers, vegetable oils, lanolin, methyl ketone, among others.
- vehicular agents such as, for example, water, hydrocarbons, alcohols, polyols, ethers, vegetable oils, lanolin, methyl ketone, among others.
- binders examples of such binders are polyvinylpyrrolidone, hydroxypropylmethylcellulose, alginic acid, sodium alginate, polymethacrylate, maltodextrin, liquid glucose, aluminum silicate, hydroxypropylcellulose, aluminum magnesium silicate, starch and others.
- alginic acid sodium carboxymethylcellulose, colloidal silicon dioxide, croscaramellose sodium, crospovidone, alginate can be used sodium, cellulose powder, magnesium aluminum silicate, pregelatinized starch, and others.
- An emulsion for the transdermal or percutaneous administration of the pharmaceutical composition can be obtained with the aid of one or more emulsifying agents, such as gum arabic, tragacanth, gelosa, carragaen, pectin and the like.
- emulsifying agents such as gum arabic, tragacanth, gelosa, carragaen, pectin and the like.
- an emulsion comprises preservatives, antifungal agents and especially antioxidants.
- suspending agents for any preparation for parenteral administration are gums, alginate, methyl cellulose, hydroxyethyl cellulose, bentonite, non-ionic surfactants, acacia and carboxymethyl cellulose, among others.
- the dose depends on the active ingredient or ingredients, the specific mode of administration, the therapeutic indication and the age of the patient.
- composition of the present invention can also be administered percutaneously in the form of ointments, creams, gels, pastes.
- ointments may comprise one or more excipients of natural or synthetic origin, and may comprise additives such as antimicrobial agents, stabilizers, antioxidants, emulsifiers and / or thickeners.
- Creams are ointments of a polyphasic structure that can comprise emulsifiers such as sorbitan esters, or monoglycerides when they are hydrophobic creams, or they can comprise emulsifiers such as sodium soaps and triethanolamine, and / or mixtures of polysorbates with other emulsifiers, when they are hydrophilic creams.
- emulsifiers such as sorbitan esters, or monoglycerides when they are hydrophobic creams, or they can comprise emulsifiers such as sodium soaps and triethanolamine, and / or mixtures of polysorbates with other emulsifiers, when they are hydrophilic creams.
- the gels may comprise excipients such as liquid paraffin added to polyethylene, aluminum or zinc soaps, among others, or in the case of hydrogels, they may comprise excipients such as water, glycerol, propylene glycol, gum tragacanth, cellulose derivatives, among others.
- the present invention further relates to a method for the treatment of a chronic liver disease.
- the chronic liver disease can be liver cirrhosis, alcoholic hepatitis, viral hepatitis and simultaneous occurrences thereof.
- Particularly special said disease is liver cirrhosis.
- insulin-like growth factor type I and interferon-alpha are present in a pharmaceutical composition that is administered to said human individual.
- the insulin-like growth factor type I and interferon-alpha are administered separately.
- the administration of insulin-like growth factor type I and interferon-alpha between 20 and 200 ⁇ g / kg body weight of the patient of insulin-like growth factor type I is employed , per day.
- the chronic liver disease is hepatitis C virus
- 2 MUI to 6 MUI of interferon-alpha are used. three times per week.
- the disease is hepatitis C virus, and for the administration of insulin-like growth factor type I and interferon-alpha, 0.2 to 1.2 ⁇ g / kg of weight are used body of the patient, of interferon-alpha per week.
- chronic liver disease is hepatitis B virus, and for the administration of insulin-like growth factor type I and interferon-alpha, 1.5 MUI to 10 MUI of interferon-alpha are used three times a week.
- the chronic liver disease is hepatitis B virus, for the administration of insulin-like growth factor type I and interferon-alpha, between 4.5 and 35 MUI of interferon-alpha per week.
- interferon-alpha may be conjugated to a polymer, such as polyethylene glycol (PEG).
- PEG polyethylene glycol
- Such conjugates can be obtained prepared by methods already known in the state of the art. Various processes for obtaining and formulations containing said conjugates are described, for example, in US-5382657, US-5762923, US-5908621, US-6250469, US-6524570 and EP-809996, the content of which is incorporated herein descriptive by reference.
- the experimental design includes healthy controls (CO), untreated cirrhotic animals (IC), cirrhotic rats treated with IGF-I (CI + IGF, 2 ⁇ g-100g of patient's body weight -day "1 ), cirrhotic rats treated with IFN alpha (CI + IFN, 3,200 IU, three days / week) and cirrhotic rats treated with both factors (CI + IGF + IFN) for three weeks.
- An advantage of the present invention is therefore that the co-administration of IGF-I + IFN- ⁇ enhances the hepatoprotective and antifibrogenic effects known only in IGF-I therapy. Both factors improve liver function tests, lipid peroxidation in cirrhotic liver and induce a remarkable histopathological recovery. These results suggest that IGF-I and IFN- ⁇ appear to act by different mechanisms, resulting in a more effective action on the cirrhotic liver.
- Figure IA shows serum concentrations of total proteins on day 22, in the different groups of cirrhotic animals and in the group of healthy controls.
- Figure IB shows serum concentrations of total proteins before and after treatment, on day 0 and day 22, in the groups of cirrhotic animals treated with
- IGF-I or with IFN, or with both, demonstrating the anabolic effect of IGF-I, which is not observed only with IFN.
- Figure 2A shows serum albumin concentrations in different groups of cirrhotic animals compared to control animals, on day 22.
- Figure 2B shows the evolution of serum albumin concentrations in different groups of cirrhotic animals treated with IGF-I, or with IFN- ⁇ , or with both, on day 0 and day 22, and the effect of therapy with IGF-I. It is observed that IGF-I therapy increases serum albumin concentrations. This effect was not observed in cirrhotic animals treated with IFNa only.
- Figure 3A shows the concentration of bilirubin in the day 22, for the groups of cirrhotic animals compared to the control animals, checking the efficacy of all treatments in reducing this cholestasis parameter.
- Figure 3B shows the evolution before and after the bilirubinemia treatment, that is, on day 0 and day 22 for groups of cirrhotic animals treated with IGF-I, or with IFN- ⁇ , or with both.
- Figure 4A shows serum cholesterol concentrations in all experimental groups on day 22. Hypercholesterolemia was tested in untreated cirrhotic animals, IFN- ⁇ did not modulate this parameter and co-administration of IGF-I + IFN- ⁇ was particularly effective.
- Figure 4B shows cholesterol levels before and after treatment in animals treated with IGF-I, or with IFN- ⁇ , or both.
- Figure 5A shows the alkaline phosphatase levels of cirrhotic animals and controls on day 22. A notable increase in this parameter of cholestasis was observed in animals only treated with IFN-alpha, while co-administration of both factors was able to normalize this parameter.
- Figure 5B shows the evolution of alkaline phosphatase concentrations before and after treatment with IGF-I, or with IFN- ⁇ , or both.
- Figure 6A shows serum concentrations of aspartate aminotransferase (ASAT) in cirrhotic animals and control animals on day 22.
- ASAT aspartate aminotransferase
- Figure 6B shows the evolution of serum concentrations of ASAT before and after treatment with IGF-I, or with IFN- ⁇ , or both.
- Figure 7A shows the levels of alanine aminotransferase (ALAT) of cirrhotic animals and controls on day 22, at the end of treatment.
- ALAT alanine aminotransferase
- FIG. 7B shows the evolution of concentrations in Alanine aminotransferase (ALAT) serum before and after treatment with IGF-I, or with IGF-I and IFN- ⁇ simultaneously.
- Alanine aminotransferase AAT
- Figure 8 shows the concentration of malonic dialdehyde as a marker of liver lipid peroxidation levels in cirrhotic animals not treated or treated with the three treatments studied, a significant reduction being observed in the two groups treated with IGF-I.
- Figure 9 shows the degree of liver fibrosis expressed as a semi-quantitative index, where the symbols have the following meaning: *** p ⁇ 0.001 vs Healthy Controls (CO), &&& p ⁇ 0.001 vs untreated cirrhotic animals (IC), # p ⁇ 0.05 vs
- Figure 10 shows liver cirrhosis confirmation
- Figure 11 shows several fields of the liver histopathological appearance of cirrhotic animals treated with IFN- ⁇ for three weeks (group CI + IFN- ⁇ ). (sections 4 ⁇ m; staining with Masson's trichrome staining; various magnifications). A decrease in the number, length and thickness of the fibrous septa was found in this group treated with IFN. However, numerous areas of tissue damage were observed.
- Figure 12 shows the histopathological appearance of the liver of cirrhotic rats treated with IGF-I for three weeks (group CI + IGF-I). (4 ⁇ m sections; Masson's trichrome staining; various magnifications). A reduction of the Fibrosis in cirrhotic rats treated with IGF-I, when compared with the untreated cirrhotic group (Fig. 1).
- Figure 13 shows the histopathological results in animals that received co-administration of IGF-I and IFN- ⁇ (group CI + IGF + IFN). (4 ⁇ m sections; Masson's trichrome staining, - various magnifications). A very noticeable decrease in collagen deposits and a clear recovery of normal liver architecture was observed, with steatosis.
- Figure 14 shows a comparative study including the four cirrhotic groups without treatment or treated with each of the proposed factors or with the co-administration of both. A clear improvement in liver histology was found with the three treatments (CI + IFN, CI + IGF and CI + IFN + IGF). Co-administration of the two factors induced a more effective response.
- I IGGFF - II insulin-like growth factor I
- MDA malonic dialdehyde
- - rhIGF human recombinant factor IGF-I
- the animals were sacrificed by decapitation 24 hours after receiving the last dose (day 22).
- the biochemical parameters were determined on day 0 and on 22.
- Blood was drawn from the retroocular venous plexus with capillary tubes (70 mm; Marienfeld, Germany), divided into aliquots, and stored at -20 0 C until use .
- the livers were weighed and a sample of the left major lobe of the liver (fixed in Bouin solution) was processed to perform the histological examination Tissue samples were immediately frozen by immersion in liquid N 2 and stored at -80 0 C until assays. All animals included in the groups that received CCl 4 had liver function tests altered on day 0, before the start of treatments, and liver biopsy on day 22 confirmed the establishment of cirrhosis.
- the malonic dialdehyde (MDA) was used as the lipid peroxidation index in liver homogenates, which was determined after heating the samples at 45 ° C for 60 minutes in an acid medium. It was quantified by a colorimetric assay using LPO-586 (Bioxytech; OXIS International Inc., Portland, OR), which after reacting with MDA, generates a chromophore, which can be measured at 586 nm (Hitachi U2000 Spectro; Boehringer Mannheim) . The titrations were performed in homogenates of liver tissue in Tris-HCl solution (1 g of liver tissue / 10 mL), centrifuged at 300Og- for 10 minutes at 4 ° C.
- the width of the fibrous septa was calculated with a magnification of 150X adding: 4 points when the average value of the thickness of 9 septa (3 periportals, 3 perivenoses, and 3 perinodulars), measured in four different areas, ranged between 90-125 ⁇ m ; score 3, 70-50 ⁇ m; and score 2, ⁇ 40-30 ⁇ m.
- the number of septa was scored as:
- a semi-quantitative determination of fibrosis was made using a numerical scoring system, based on the number, length and thickness of the fibrous septa .
- IFN- ⁇ therapy did not produce a clear hepatoprotection (histologically) because large areas of the parenchyma appear to be damaged.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2004/000380 WO2006032711A1 (es) | 2004-08-18 | 2004-08-18 | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2004/000380 WO2006032711A1 (es) | 2004-08-18 | 2004-08-18 | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006032711A1 true WO2006032711A1 (es) | 2006-03-30 |
Family
ID=36089874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2004/000380 WO2006032711A1 (es) | 2004-08-18 | 2004-08-18 | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006032711A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010009762A1 (en) * | 2008-07-23 | 2010-01-28 | United Technologies Ut Ag | Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2138565A1 (es) * | 1998-05-13 | 2000-01-01 | Inst Cientifico Tecnol Navarra | Uso del interferon alfa 5 en el tratamiento de las haepatopatias virales. |
ES2160927T3 (es) * | 1996-02-28 | 2001-11-16 | Unihart Corp | Composiciones farmaceuticas que comprenden interferon alfa humano natural. |
US20020028764A1 (en) * | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
-
2004
- 2004-08-18 WO PCT/ES2004/000380 patent/WO2006032711A1/es not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2160927T3 (es) * | 1996-02-28 | 2001-11-16 | Unihart Corp | Composiciones farmaceuticas que comprenden interferon alfa humano natural. |
ES2138565A1 (es) * | 1998-05-13 | 2000-01-01 | Inst Cientifico Tecnol Navarra | Uso del interferon alfa 5 en el tratamiento de las haepatopatias virales. |
US20020028764A1 (en) * | 2000-09-04 | 2002-03-07 | Aarhus Amt. | Treatment of acute and chronic liver disease |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
Non-Patent Citations (6)
Title |
---|
DATABASE BIOSIS [online] BRACZKOWSKI R. ET AL: "Declination of IGF-1 level in children treated with Interferon alpha due to chronic hepatitis type B", Database accession no. (PREV200000476358) * |
DATABASE BIOSIS [online] CONCHILLO M. ET AL: "Results of a randomized double-blind, controlled pilot study of the administration of insulin like growth factor-1 (IGF-1) in patients with liver cirrhosis", Database accession no. (PREV200400396087) * |
DATABASE BIOSIS [online] DEL MONTE PATRIZIA: "Endocrine evaluation in patients treated with interferon-alpha for chronic hepatitis C", Database accession no. (PREV199598495345) * |
HORMONE RESEARCH, vol. 44, no. 3, 1995, pages 105 - 109 * |
IMMUNOLOGY LETTERS, vol. 73, no. 2-3, September 2000 (2000-09-01), pages 201 * |
JOURNAL OF HEPATOLOGY, vol. 40, no. 1, April 2004 (2004-04-01), pages 59 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010009762A1 (en) * | 2008-07-23 | 2010-01-28 | United Technologies Ut Ag | Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Diamond et al. | Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation | |
US9480649B2 (en) | Lipid microparticle growth factor formulations | |
US4548922A (en) | Drug administration | |
KR20160091434A (ko) | 재조합 vwf 제제 | |
WO2002053167A2 (es) | Combinacion farmaceutica para el tratamiento del dano tisular debido a falta de irrigacion sanguinea arterial | |
ZA200401360B (en) | Hdl for the treatment of stroke and other ischemic conditions | |
WO1995029694A1 (fr) | Accelerateur d'hydrolyse du collegene | |
SG194865A1 (en) | Controlled release peptide formulations | |
JP2007269778A (ja) | 黄斑変性症及び関連眼状態の治療方法 | |
JP7089011B2 (ja) | 急性呼吸促迫症候群治療剤 | |
EP2421548A1 (en) | Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy | |
ES2248935T3 (es) | Medicamento topico con un contenido de ciclosporina. | |
JP2010516671A (ja) | 糖尿病の治療のためのエクセナチド及びダラルギンに基づく医薬、その使用及び治療方法 | |
EP1890705B1 (en) | Use of 24-nor-UDCA for the treatment of cholestatic liver diseases | |
CN105579052A (zh) | 药物组合物 | |
US6566331B1 (en) | Treatment of collagen related diseases | |
Neiderhiser | Acute acalculous cholecystitis induced by lysophosphatidylcholine. | |
US20070116755A1 (en) | Dissolution of arterial cholesterol plaques by pharmacological preparation | |
WO2006032711A1 (es) | Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden | |
PT94223B (pt) | Metodo para o tratamento de processos patologicos associados ao intestino, catabolicos e defesas enfraquecidas do hospedeiro, utilizando glutamina | |
EP0821969A2 (en) | Medicinal Composition comprising TCF-II | |
ES2303492A1 (es) | Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden. | |
WO2007096745A1 (en) | Methods for the treatment of macular degeneration and related eye conditions | |
Zheng et al. | Surfactant and inhaled nitric oxide in rats alleviate acute lung injury induced by intestinal ischemia and reperfusion | |
ES2201128T3 (es) | Agente terapeutico para alteraciones del metabolismo de lipidos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 200750016 Country of ref document: ES Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P200750016 Country of ref document: ES |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 200750016 Country of ref document: ES Kind code of ref document: A |
|
WWR | Wipo information: refused in national office |
Ref document number: 200750016 Country of ref document: ES Kind code of ref document: A |